ATE307589T1 - Verabreichung von produkten des 5- lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr - Google Patents

Verabreichung von produkten des 5- lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr

Info

Publication number
ATE307589T1
ATE307589T1 AT97954070T AT97954070T ATE307589T1 AT E307589 T1 ATE307589 T1 AT E307589T1 AT 97954070 T AT97954070 T AT 97954070T AT 97954070 T AT97954070 T AT 97954070T AT E307589 T1 ATE307589 T1 AT E307589T1
Authority
AT
Austria
Prior art keywords
administration
products
metabolism products
antimicrobial defense
increase antimicrobial
Prior art date
Application number
AT97954070T
Other languages
English (en)
Inventor
Marc Peters-Golden
Theodore Standiford
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE307589T1 publication Critical patent/ATE307589T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97954070T 1996-12-03 1997-12-03 Verabreichung von produkten des 5- lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr ATE307589T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/757,136 US5909734A (en) 1996-12-03 1996-12-03 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
PCT/US1997/022635 WO1998024397A2 (en) 1996-12-03 1997-12-03 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense

Publications (1)

Publication Number Publication Date
ATE307589T1 true ATE307589T1 (de) 2005-11-15

Family

ID=25046516

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05016311T ATE457730T1 (de) 1996-12-03 1997-12-03 Verabreichung von produkten des 5-lipoxygenase synthesewegs zur behandlung von mikrobiellen infektionen
AT97954070T ATE307589T1 (de) 1996-12-03 1997-12-03 Verabreichung von produkten des 5- lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05016311T ATE457730T1 (de) 1996-12-03 1997-12-03 Verabreichung von produkten des 5-lipoxygenase synthesewegs zur behandlung von mikrobiellen infektionen

Country Status (9)

Country Link
US (3) US5909734A (de)
EP (2) EP1602375B1 (de)
AT (2) ATE457730T1 (de)
AU (1) AU733567B2 (de)
CA (1) CA2278140C (de)
DE (2) DE69734476T2 (de)
DK (1) DK1037640T3 (de)
ES (2) ES2341255T3 (de)
WO (1) WO1998024397A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473708B2 (en) 1996-02-15 2009-01-06 Jean Gosselin Agents with leukotriene B4-like antiviral (enveloped RNA) activities
US5909734A (en) * 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
KR100325581B1 (ko) * 1998-08-07 2002-08-24 오우택 아라키토닉산의리폭시게네이즈대사결과물질을함유하는진통제용조성물
WO2004112795A1 (en) * 2003-06-25 2004-12-29 Ltb4 Sweden Ab Ltb4 compositions for treating tract infections
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
ATE474603T1 (de) * 2004-09-20 2010-08-15 Ltb4 Sweden Ab Stabilisiertes leukotrien b4 (ltb4) pharmazeutikum
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN112546196A (zh) * 2020-02-29 2021-03-26 中国人民解放军总医院第三医学中心 肌动蛋白聚合诱导剂在制备抵抗或抑制肺炎克雷伯氏菌的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4821714A (en) * 1986-12-04 1989-04-18 Smelser Danny N Pharmaceutical endotracheal tube
US5314918A (en) * 1987-06-24 1994-05-24 Smithkline Beecham Corporation Leukotriene antagonists
US5145861A (en) * 1987-11-04 1992-09-08 Merrell Dow Pharmaceuticals Inc. Fluorinated arachidonic acid derivatives
DK0629213T3 (da) * 1992-03-07 1996-11-18 Morinaga Milk Industry Co Ltd Anvendelse af et immunstimulerende middel
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5909734A (en) * 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense

Also Published As

Publication number Publication date
ATE457730T1 (de) 2010-03-15
US20050267211A1 (en) 2005-12-01
WO1998024397A2 (en) 1998-06-11
US5909734A (en) 1999-06-08
US7696148B1 (en) 2010-04-13
ES2341255T3 (es) 2010-06-17
EP1602375A3 (de) 2005-12-14
WO1998024397A3 (en) 1998-09-03
CA2278140A1 (en) 1998-06-11
EP1037640B1 (de) 2005-10-26
EP1602375B1 (de) 2010-02-17
CA2278140C (en) 2008-02-05
DE69734476D1 (de) 2005-12-01
AU733567B2 (en) 2001-05-17
DE69739775D1 (de) 2010-04-01
EP1037640A2 (de) 2000-09-27
EP1602375A2 (de) 2005-12-07
DK1037640T3 (da) 2006-03-13
EP1037640A4 (de) 2003-07-23
AU5794298A (en) 1998-06-29
ES2251748T3 (es) 2006-05-01
DE69734476T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
NZ514260A (en) A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections
ATE207755T1 (de) Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen
IL106842A (en) Pharmaceutical compositions comprising il-4r or derivatives thereof for the treatment, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases and fungal infections
NO991548L (no) Anvendelse av mupirocin for fremstilling av et medikament for behandling av bakterieinfeksjoner forÕrsaket i forbindelse med kolonisering av nasofarynks med patogene organismer
EP1037640A4 (de) Verabreichung von produkten des 5-lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
EE03597B1 (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini
EP1013282A3 (de) Arznei- und Nahrungsmittel enthaltend Transferrine und antibakterielle Wirkstoffe zur Förderung der Immunabwehr und zur Behandlung von Infektionen
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
KR950026524A (ko) 피부질환 치료용 의약조성물
DE69419782D1 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ATE121459T1 (de) Antibiotika ge 2270 faktoren b1, b2, c1, d1, d2, e und t.
JPS6483025A (en) Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
ATE413170T1 (de) Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus
BR0318497A (pt) composto de droga antibacteriana compreendendo n-acetil-d-glucosamina
RU2003347C1 (ru) Средство дл лечени протейной инфекции
RU94024111A (ru) Способ профилактики кишечных инфекций
HK40087462A (en) New recombinant lysin and its use in the treatment of gram-negative bacterial infections
LEE et al. A Case of Sepsis due to Vibrio damsela
Kitahara Methods of enhancing the treatment of infections- Secrets to the selection and use of antibiotics
RU94024117A (ru) Способ лечения гастроэнтероколита
Sgromo et al. Hyperbaric oxygen therapy in anaerobic infection(sepsis) in children.
Ratliff et al. Replantation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1037640

Country of ref document: EP